Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "Narcolepsy Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
The U. S. Market is Estimated at $489.6 Million, While China is Forecast to Grow at 14.9% CAGR
Amid the COVID-19 crisis, the global market for Narcolepsy Therapeutics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 11.3% over the analysis period 2020-2027.
Narcolepsy with Cataplexy, one of the segments analyzed in the report, is projected to record a 11% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Narcolepsy without Cataplexy segment is readjusted to a revised 12% CAGR for the next 7-year period.
The Narcolepsy Therapeutics market in the U. S. is estimated at US$489.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$828.9 Million by the year 2027 trailing a CAGR of 14.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.
Secondary Narcolepsy Segment to Record 9.6% CAGR
In the global Secondary Narcolepsy segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$53.5 Million in the year 2020 will reach a projected size of US$97.9 Million by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$563.1 Million by the year 2027, while Latin America will expand at a 10.9% CAGR through the analysis period. We bring years of research experience to this 16th edition of our report. The 257-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others:
- Arena Pharmaceuticals, Inc.
- BioProjet Pharma
- Graymark Healthcare, Inc.
- Jazz Pharmaceuticals PLC
- Ligand Pharmaceuticals, Inc.
- Shionogi, Inc.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Global Competitor Market Shares
- Narcolepsy Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2028
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
For more information about this report visit https://www.researchandmarkets.com/r/9sz505
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.